A K Dembélé1, B A Toure1, Y S Sarro1, A Guindo1, B Fané1, L Offredo2, S Kené1, I Conaré3, O Tessougué1, Y Traoré1, Y Badiaga1, M B Sidibé1, D Diabaté1, M Coulibaly1, M Kanta1, B Ranque2, D A Diallo4. 1. Centre de recherche et de lutte contre la drépanocytose (CRLD), point G, commune III, 03 BP 186, BKO 03, Bamako, Mali. 2. UMR_S970, Inserm, hôpital européen Georges-Pompidou, AP-HP, université Paris Descartes, 15, rue Le-Blanc, 75908 Paris cedex 15, France. 3. Institut d'ophtalmologie tropicale de l'Afrique de l'Ouest (IOTA), Bamako, Mali. 4. Centre de recherche et de lutte contre la drépanocytose (CRLD), point G, commune III, 03 BP 186, BKO 03, Bamako, Mali; Service d'hématologie-oncologie médicale du CHU du point G, BP 333, Bamako, Mali. Electronic address: dadiallo@icermali.org.
Abstract
INTRODUCTION: Retinopathy is a chronic complication with severe functional consequences in patients with sickle cell disease. Its prevalence is not well known in sub-Saharan Africa because of the absence of screening. We report here the results of a routine screening for sickle retinopathy in a Comprehensive Sickle Cell Center in Sub-Saharan Africa. METHODS: Screening of sickle retinopathy was carried out in all sickle cell patients aged 10 and over, followed between 2010 and 2012. Retinopathy was screened by dilated indirect fundoscopic examination and retinal angiography, if necessary. The gender, age and hematological parameters of patients with sickle retinopathy were compared with those of controls randomly selected from the cohort of sickle cell patients without retinopathy followed during the same period. RESULTS: The overall prevalence of sickle cell retinopathy was 8.8% (142/1604): 12.4% (91/731) in SC, 5.2% (38/734) in SS, 9.4% (5/53) in Sβ°-thalassemia patients and 9.3% (8/86) in Sβ+-thalassemia patients. Proliferative retinopathy was more common in SC patients (P<0.01). High levels of hemoglobin or of hematocrit were associated with retinopathy in all patients and with proliferative retinopathy in SC patients. In SS or Sβ0thalassemia patients, high leukocyte count was associated with proliferative retinopathy. Low fetal hemoglobin level was associated with retinopathy in all groups. CONCLUSION: The prevalence of sickle cell retinopathy is high and negatively associated to the level of fetal hemoglobin. The efficiency of a routine screening for sickle cell retinopathy must be assessed in Africa as well as the benefit of phlebotomy and hydroxyurea therapy as a preventive treatments.
INTRODUCTION:Retinopathy is a chronic complication with severe functional consequences in patients with sickle cell disease. Its prevalence is not well known in sub-Saharan Africa because of the absence of screening. We report here the results of a routine screening for sickle retinopathy in a Comprehensive Sickle Cell Center in Sub-Saharan Africa. METHODS: Screening of sickle retinopathy was carried out in all sickle cell patients aged 10 and over, followed between 2010 and 2012. Retinopathy was screened by dilated indirect fundoscopic examination and retinal angiography, if necessary. The gender, age and hematological parameters of patients with sickle retinopathy were compared with those of controls randomly selected from the cohort of sickle cell patients without retinopathy followed during the same period. RESULTS: The overall prevalence of sickle cell retinopathy was 8.8% (142/1604): 12.4% (91/731) in SC, 5.2% (38/734) in SS, 9.4% (5/53) in Sβ°-thalassemiapatients and 9.3% (8/86) in Sβ+-thalassemiapatients. Proliferative retinopathy was more common in SC patients (P<0.01). High levels of hemoglobin or of hematocrit were associated with retinopathy in all patients and with proliferative retinopathy in SC patients. In SS or Sβ0thalassemia patients, high leukocyte count was associated with proliferative retinopathy. Low fetal hemoglobin level was associated with retinopathy in all groups. CONCLUSION: The prevalence of sickle cell retinopathy is high and negatively associated to the level of fetal hemoglobin. The efficiency of a routine screening for sickle cell retinopathy must be assessed in Africa as well as the benefit of phlebotomy and hydroxyurea therapy as a preventive treatments.
Authors: Elie Abitbol; Alexandra Miere; Jean-Baptiste Excoffier; Carl-Joe Mehanna; Francesca Amoroso; Samuel Kerr; Matthieu Ortala; Eric H Souied Journal: BMJ Open Ophthalmol Date: 2022-02-04